临床肝胆病杂志2017，Vol.33Issue(4)：746-750,5.DOI:10.3969/j.issn.1001-5256.2017.04.035
妊娠期应用替比夫定降低HBV母婴传播风险的研究进展
Research advances in the application of telbivudine during pregnancy to prevent HBV mother-to-child transmission
摘要
Abstract
Almost 10％ of neonates whose mothers have a high HBV DNA load may have HBV infection,even after the preventive treatment with hepatitis B vaccine and immune interruption.In pregnant women with a high HBV DNA load,nucleos (t) ide analogues (lamivudine,telbivudine,and tenofovir) have been used in the second and third trimesters to improve the interruption of mother-to-child transmission of hepatitis B.This article reviews the strategies for antiviral therapy with telbivudine for pregnant women with a high HBV DNA load in their third trimester,changes in maternal HBV DNA level after antiviral therapy,whether the success rate of interruption of mother-to-child transmission can be further increased,safety in mothers and infants,the most appropriate time for drug administration and withdrawal,and breastfeeding issues.关键词
肝炎病毒,乙型/疾病传播,垂直/治疗/孕妇/综述Key words
hepatitis B virus/disease transmission, vertical/therapy/pregant women/review分类
医药卫生引用本文复制引用
王崇,曹梦琢,王川,姜晶,李杰,牛俊奇..妊娠期应用替比夫定降低HBV母婴传播风险的研究进展[J].临床肝胆病杂志,2017,33(4):746-750,5.基金项目
十二五国家科技重大专项课题子课题(2012ZX10002001-001) （2012ZX10002001-001）
吉林省卫生计生科研计划(20152003) （20152003）
中国肝炎防治基金会-天晴肝病基金资助课题(TQGB20140137) （TQGB20140137）
